Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -28.3% | 0% | 87.6% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $0 | -$1 | -$1 | -$0 |
| % Margin | 0% | -164.3% | -164.3% | -81.1% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $2 |
| Operating Income | -$1 | -$2 | -$2 | -$2 |
| % Margin | -347.5% | -486.8% | -486.8% | -1,098.5% |
| Other Income/Exp. Net | $1 | -$0 | -$0 | $0 |
| Pre-Tax Income | $0 | -$2 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | -764.5% | -534.8% | -400.8% | -1,082.5% |
| EPS | -18,960 | -1.2 | -1.2 | -5.6 |
| % Growth | -1,579,900% | 0% | 78.6% | – |
| EPS Diluted | -18,960 | -1.2 | -1.2 | -5.6 |
| Weighted Avg Shares Out | 0 | 2 | 1 | 0 |
| Weighted Avg Shares Out Dil | 0 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$1 | -$2 |
| % Margin | -347.5% | -395.7% | -217.6% | -809.2% |